Peptide Evidence Levels Explained

What an evidence label can tell you

PepCodex dossiers can show one overall Evidence Level badge for a compound. The four labels are high, moderate, low, and very low. This is a broad editorial signal about the compound’s research record. It is not a separate evidence grade for every indication, population, benefit, or safety outcome. Read the badge alongside the precise claim and its cited studies; it is not a safety guarantee or a recommendation to use a peptide.

These labels resemble the four names used by GRADE, but a PepCodex compound badge is not a formal GRADE assessment. Formal GRADE evaluates a body of evidence for a defined outcome and examines its limitations. The Oxford Centre for Evidence-Based Medicine levels are another way to locate likely useful study designs; their numbered levels are not interchangeable with these four badges.

Compound badge	What not to infer from it
High	It does not establish high certainty for every claim about the compound.
Moderate	It is not a formal, outcome-specific GRADE rating of moderate certainty.
Low	It does not show that the compound has no effect for every outcome.
Very low	It does not by itself prove that a proposed effect is absent or that a product is unsafe.

The badge is not assigned separately to each outcome, and this table does not define a trial-count or phase threshold for it. To assess a particular claim, review the relevant human evidence and its limits. An individual randomized trial can have important limitations; an animal result cannot, by itself, establish a benefit in people. GRADE considers risk of bias, inconsistency, indirectness, imprecision, and publication bias when assessing confidence in an effect estimate. PMID: 21208779

Start with the claim, not the compound

When you see a compound badge, ask which population, comparison, outcome, and time frame the evidence behind the claim addresses. A study of weight change in adults without diabetes cannot establish every effect of the same compound in people with diabetes, children, or other populations. Evidence for benefit also does not settle every safety question. The relevant studies and limitations may differ for each claim. PMID: 18436948

Then inspect the sources: Was the outcome measured in people? Was there a suitable comparator? Could bias, missing data, inconsistent findings, or a wide range of plausible effects change the conclusion? A phase number tells you where a trial sits in development; it does not answer those questions on its own. The Oxford levels and introductory material emphasize using judgment with any study hierarchy.

Keep approval and evidence separate

FDA approval reflects a benefit-risk review for a specified use and population. It does not turn every possible claim about a drug into high-certainty evidence. Likewise, a compound’s low badge does not prove a treatment has no effect for a specific outcome. An evidence badge is not medical advice.

For a source-by-source example, read how a semaglutide weight-loss trial relates to a compound evidence badge. The example stays within the trial’s population and outcome instead of treating the badge as proof for every claim.

Sources & Citations

• 1

  journal

  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

  pmid-18436948

• 2

  journal

  GRADE guidelines: 3. Rating the quality of evidence

  pmid-21208779

• 3

  source

  OCEBM Levels of Evidence

  oxford-cebm-levels

• 4

  regulatory

  Development & Approval Process | Drugs

  fda-drug-approval-process